Pharmaceutical Regulation Under Gottlieb-Trump - Webinar Recording/Transcript
Pharmaceutical Regulation under Gottlieb-Trump
In Part III of FDAnews’s Expert Insight Series, our panel takes up drug regulation, policy and enforcement.
It will be 10 months into the Trump administration and the drug regulation picture will be coming clearer. New drug policies will have been established. New Trump-Gottlieb appointees will be assuming office. Many new products will have been approved. And it will be coming clear how fundamental standards for approval will differ from the past.
Perhaps most important, specific policies will be starting to emerge: Product approvals, opioids, drug pricing, and more.
Given the fluid nature of events though, panelists are certain to range beyond the topic of the day. Even if you haven’t participated previously, be certain to take in the final session where panelists look to the shape of things to come — 2018, 2019 and beyond. Multiple registration is a bargain, with special pricing to lower your costs. Other installments include:
- What We’ve Learned Since Scott Gottlieb Was Confirmed
- Device Regulation under Gottlieb & Trump
- Global Regulation under Gottlieb-Trump and a Look Ahead
If you are in drugs or biologics, you know this is the must-attend session.